683 Capital Management’s ClearPoint Neuro CLPT Stock Holding History

683 Capital Management’s Portfolio CLPT Stock Details CLPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-54,387	Closed	-$836K	–	163
2024 Q4	$836K	Buy	+54,387	New	+$704K	0.05%	114
2023 Q2	–	Sell	-19,362	Closed	-$163K	–	190
2023 Q1	$163K	Hold	19,362	–	–	0.01%	191
2022 Q4	$164K	Buy	+19,362	New	+$184K	0.01%	212
2021 Q1	–	Sell	-20,690	Closed	-$329K	–	188
2020 Q4	$329K	Buy	+20,690	New	+$186K	0.02%	177

Other funds holding CLPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

EIM

Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CWM

Cahill Wealth Management Portage, Michigan $196M AUM 8.5% 1-Year Est. Return

683 Capital Management's CLPT Position: Q1 2025 in Review

683 Capital Management sold out of ClearPoint Neuro (CLPT) in Q1 2025, closing a stake of 54,387 shares — an estimated $836K sold.

683 Capital Management first reported a position in CLPT in Q4 2020 and held it in 4 quarters. The position peaked at $836K in Q4 2024. 101 funds tracked by Wall St. Rank hold CLPT as of Q1 2025.

683 Capital Management reported no remaining ClearPoint Neuro position as of Q1 2025 after selling out during the quarter.
683 Capital Management sold 54,387 ClearPoint Neuro shares in Q1 2025, an estimated $836K.
683 Capital Management first reported a position in ClearPoint Neuro in Q4 2020 and held it in 4 quarters.
683 Capital Management's ClearPoint Neuro position peaked at $836K in Q4 2024.
101 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q1 2025.

Based on 683 Capital Management's 13F filing for Q1 2025, filed 15 May 2025.